CoreAge Rx vs Kina
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Kina head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 69 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make Kina a bad call — it's best for women seeking midlife-focused clinical support who can confirm the medication, complete bill and applicable cancellation terms. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | Kina |
|---|---|---|
| Brief Score | 94/100 (A) | 69/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Confirm medication + care total Injection advertised at $199/mo ongoing. The no-membership offer conflicts with separate-fee language in general terms. Full price detailsCompounded semaglutide offered; complete quote unknown because membership terms conflict; injection advertised $199/month ongoing; earlier listing: From $179/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Confirm medication + care total Injection advertised at $249/mo ongoing. The no-membership offer conflicts with separate-fee language in general terms. Full price detailsCompounded tirzepatide offered; complete quote unknown because membership terms conflict; injection advertised $249/month ongoing; earlier listing: From $179/mo (starting dose, compounded) |
| Coverage | US only; restrictions by state, confirmed at intake | Care depends on clinician and pharmacy licensing in your location; no complete current state roster established |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
Kina: Ongoing injections list $199 semaglutide/$249 tirzepatide. Complete totals remain unconfirmed because general terms describe membership and separately billed medication.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.